Syros Pharmaceuticals, Inc. (SYRS)
Restoring healthy gene expression and myeloid differentiation. At Syros Pharmaceuticals, we're on a mission to offer hope to patients with blood disorders through biologically targeted solutions.
Syros Pharmaceuticals Shares Plummet Premarket After Study …
2 days ago · Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer ...
Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default
2 days ago · Syros Pharmaceuticals on Tuesday reported that its oral drug candidate tamibarotene failed the Phase III SELECT-MDS-1 trial, as it did not significantly improve complete response rates in certain patients with myelodysplastic syndrome compared to the approved drug azacitidine plus placebo. The failure “constitutes an event of default under its secured loan …
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial …
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk ...
Syros Pharmaceuticals, Inc. (SYRS) - Yahoo Finance
Find the latest Syros Pharmaceuticals, Inc. (SYRS) stock quote, history, news and other vital information to help you with your stock trading and investing.
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial …
3 days ago · About Syros Pharmaceuticals. Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
Syros Highlights Anticipated 2024 Milestones to Deliver on the …
CAMBRIDGE, Mass., January 08, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic...
Investor Relations :: Syros Pharmaceuticals, Inc. (SYRS)
3 days ago · Syros is driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, and we aim to develop new standards of care for the frontline treatment of patients with hematologic malignancies. We are currently developing tamibarotene for HR-MDS patients with RARA gene overexpression.
Syros Pharmaceuticals Inc (SYRS) Stock Price & News - Google
Get the latest Syros Pharmaceuticals Inc (SYRS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer
1 day ago · Syros Pharmaceuticals Inc SYRS revealed on Tuesday that the SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint of complete response rate.. The trial assessed tamibarotene ...
- Some results have been removed